ARNA - Arena Pharmaceuticals, Inc.
| Previous Close | 56.50 |
| Open | 56.64 |
| Bid | 54.48 x 800 |
| Ask | 58.00 x 1300 |
| Day's Range | 54.73 - 56.68 |
| 52 Week Range | 31.97 - 59.13 |
| Volume | 504,642 |
| Avg. Volume | 523,696 |
| Market Cap | 2.742B |
| Beta (3Y Monthly) | 1.11 |
| PE Ratio (TTM) | 4.43 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Insider Monkey•2 days ago
Did Hedge Funds Drop The Ball On Arena Pharmaceuticals, Inc. (ARNA)
The Insider Monkey team has completed processing the quarterly 13F filings for the March quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors experienced strong gains on the back of a strong market performance, which certainly propelled them to adjust their equity holdings so as […]
- Thomson Reuters StreetEvents•3 days ago
Edited Transcript of ARNA earnings conference call or presentation 8-May-19 8:30pm GMT
Q1 2019 Arena Pharmaceuticals Inc Earnings Call
- Investopedia•6 days ago
Top Marijuana Stocks on the NASDAQ
The cannabis industry has grown in recent months and years, and many companies in the cannabis and health-related industries have been uplisted to reputable U.S. exchanges. Learn about the marijuana stocks on the Nasdaq.
- Zacks•9 days ago
Why Is Arena Pharmaceuticals (ARNA) Up 9.1% Since Last Earnings Report?
Arena Pharmaceuticals (ARNA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Simply Wall St.•10 days ago
Does Market Volatility Impact Arena Pharmaceuticals, Inc.'s (NASDAQ:ARNA) Share Price?
If you own shares in Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) then it's worth thinking about how it contributes to...
- Market Realist•last month
Cannabis Sector Weekly Update: Sell-Off amid Market Weakness
Cannabis Sector Weekly Update: Sell-Off amid Market WeaknessCannabis weekly updateLast week, cannabis ETFs fell for the second consecutive week. The Horizons Marijuana Life Sciences ETF (HMMJ) saw a negative price action of 3.1%, while the ETFMG
- Zacks•last month
All You Need to Know About Arena Pharmaceuticals (ARNA) Rating Upgrade to Buy
Arena Pharmaceuticals (ARNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
Motley Fool•last monthArena Pharmaceuticals Inc (ARNA) Q1 2019 Earnings Call Transcript
ARNA earnings call for the period ending March 31, 2019.
- Simply Wall St.•last month
Did Business Growth Power Arena Pharmaceuticals's (NASDAQ:ARNA) Share Price Gain of 226%?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
- MarketWatch•last month
S&P 500, Nasdaq end lower for fourth day after Trump claims China ‘broke the deal’
U.S. stocks bounce back from intraday lows Thursday but the S&P 500 and the Nasdaq finished lower for a fourth session as trade tensions ramped up after U.S. President Donald Trump threatened tariff retaliation on China, which he claims “broke the deal”.
- Zacks•last month
Arena Pharmaceuticals' (ARNA) Loss Widens in Q1 But Stock Up
Arena Pharmaceuticals (ARNA) reports loss in the first quarter of 2019 on an adjusted basis. Revenues of $801.1 million include upfront payment of $800 million from United Therapeutics.
- MarketWatch•last month
Arena Pharmaceutical shares slide after drug maker reports disappointing financial results
Shares of Arena Pharmaceuticals Inc. declined in Wednesday's extended session after the drug company posted quarterly results that fell short of expectations. Arena reported it swung to a first-quarter profit of $620.1 million, or $12.53 a share, from a loss of $32 million, or 80 cents a share, a year earlier. Revenue jumped to $801.1 million versus $1.8 million. First-quarter revenue was bolstered by $800 million associated with upfront payment from United Therapeutics. Anaysts surveyed by FactSet had forecast earnings of $14 a share and revenue of $802 million. Arena shares were down 2.6% after hours.
Market Realist•last monthKey Cannabis Sector Updates: Analyst Ratings and Earnings
Key Cannabis Sector Updates: Price Action and Analyst Ratings(Continued from Prior Part)Cannabis updateLast week, Emerald Health Therapeutics (EMH) closed with losses of 9.4%. The company released its fourth-quarter and full-year 2018 earnings last
- Market Realist•last month
Cannabis Stocks Had a Mixed Performance Last Week
Key Cannabis Sector Updates: Price Action and Analyst RatingsCannabis stocksCannabis ETFs traded on a negative note last week. The Horizons Marijuana Life Sciences ETF (HMMJ) fell 1.2%, while the ETFMG Alternate Harvest ETF (MJ) gained 0.33%. The
- Zacks•last month
United Therapeutics (UTHR) Down Despite Q1 Earnings Beat
United Therapeutics (UTHR) beats estimates on both fronts in the first quarter. However, earnings and revenues decline year over year.
- Insider Monkey•2 months ago
Here’s What Hedge Funds Think About Arena Pharmaceuticals, Inc. (ARNA)
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money investors have to conduct complex analyses, spend many resources and use tools that are not always […]
- Market Realist•2 months ago
Ups and Downs in the Cannabis Space Last Week
Cannabis Updates: Price Action, Ratings, and MoreCannabis spaceThe cannabis space was mostly positive last week. The Horizons Marijuana Life Sciences ETF (HMMJ) and the ETFMG Alternate Harvest ETF (MJ) gained 5.2% and 4.2%, respectively, while the
- Benzinga•2 months ago
The New Cannabis ETF Is Already Making Additions
Although Tuesday was just YOLO's third day on the market, the fund's portfolio manager Dan Ahrens already made some additions to YOLO's roster. Greenlane Holdings Inc. (NASDAQ: GNLN), the Florida-based maker of cannabis vape hardware and related accessories, commenced an initial public offering on April 17, the day before YOLO debuted.
- Market Realist•2 months ago
Wall Street Ratings for Cannabis Stocks Last Week
Cannabis Updates: New Listings, Price Action, and Ratings(Continued from Prior Part)Cannabis The cannabis sector (HMMJ) closed in the red last week. Let’s see how analysts are rating some of the major cannabis players and analyze the changes last
- Simply Wall St.•2 months ago
What Type Of Shareholder Owns Arena Pharmaceuticals, Inc.'s (NASDAQ:ARNA)?
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! If you want to know who really controls Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), then you'll have to look at the makeup of...
Market Realist•2 months agoAnalysts Love Charlotte’s Web Holdings despite Q4 Earnings Miss
Charlotte’s Web Holdings Continues Its Good Run after Strong Q1(Continued from Prior Part)AnalystsCharlotte’s Web Holdings (CWBHF) released its fourth-quarter earnings last week and missed analysts’ estimates for both its top line as well as
Market Realist•3 months agoCharlotte’s Web Holdings Reports Record Harvest in 2018
Key Takeaways from Charlotte’s Web Holdings' Q4 Earnings(Continued from Prior Part)Record harvestCharlotte’s Web Holdings (CWBHF) posted a record harvest of 675,000 pounds last year. The company had produced 63,000 pounds of raw hemp in 2017.
- Zacks•3 months ago
Why Is Arena Pharmaceuticals (ARNA) Down 10.1% Since Last Earnings Report?
Arena Pharmaceuticals (ARNA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Market Realist•3 months ago
Charlotte’s Web Holdings Is Outperforming Peers in March
What to Expect from Charlotte’s Web Holdings' Q4 EarningsCharlotte’s Web Holdings Charlotte’s Web Holdings (CWBHF) is scheduled to release its fourth-quarter earnings on March 28 after markets close. The company plans to hold its earnings call
- SmarterAnalyst•3 months ago
These 3 Cannabis Stocks Are Set to Skyrocket, Say Analysts
The cannabis market is buzzing right now. But the recent rally in cannabis stocks has left some of the bigger names looking overvalued. For example Aurora Cannabis (ACB) - which has doubled year-to-date, is now facing a downside risk of 8% according to the Street. So with that in mind we focused in on stocks that still have massive upside potential ahead. We used TipRanks to focus in on the latest ratings from analysts with the strongest stock picking track record. Without further ado, here are three of the best cannabis stocks to be looking at right now:Aphria Has More Room to RunOver the last three years, Aphria (APHA) shares have exploded by over 850%, and according to the Street significant further upside potential lies ahead.That’s despite a horrendous 2018, which featured a hostile takeover attempt, the exit of its CEO and allegations from a short-seller that insiders profited from acquiring international businesses at highly inflated prices. This was the central accusation of a short report that roiled the stock price, and renewed concerns about the company’s corporate governance.Luckily the most serious allegations have now been refuted. A special board committee found that the price paid for businesses in Latin America was acceptable and that these assets are now progressing according to plan. And with newly-appointed chairman Irwin Simon now acting as CEO, short-seller Quintessential is appeased, tweeting: “With a new management team the company has a chance to a brighter future and we are accordingly moving on to new projects.” Simon is the founder, and former CEO of multi-billion company Hain Celestial Group.In short, this low-cost cannabis producer is ready to rebound. This is reflected by recent ratings from the Street. Most notably, top-rated Clarus analyst Noel Atkinson has just reiterated his buy rating on APHA with a price target of $19.25. This translates into sizeable upside potential of over 85% from the stock’s current share price of $9.63. (To watch Atkinson's track record, click here)According to Atkinson the company needs to stop looking back and start executing to move the ball forward. He believes Aphria’s list of near-term operational milestones is significant, and successful execution could transform the company both in terms of financial results and investor sentiment. “If management can execute, there is the potential for a very substantial re-rating of the stock price from current levels” the analyst tells investors.Overall, Wall Street’s confidence backing this cannabis stock is strong, with TipRanks analytics showcasing APHA as a Strong Buy. Based on 6 analysts polled in the last 3 months, 5 are bullish on Aphria stock, while only 1 remains sidelined. The 12-month average price target stands at $15.33, marking over 50% upside from where the stock is currently trading. (See APHA's price targets and analyst ratings on TipRanks)Zynerba Stock Looks Less FragileZynerba (ZYNE) focuses on transdermal cannabinoid therapeutics. Its goal is to improve the lives of patients affected by rare neuropsychiatric conditions including Fragile X syndrome and autism spectrum disorder. Currently the company is trialing a groundbreaking cannabinoid (CBD) gel. This is the first and only patented permeation-enhanced CBD gel for delivery through the skin and into the circulatory system.According to ZYNE, the gel offers multiple advantages when compared to the more traditional oral delivery. By skipping the digestive process, ZYNE can minimize psychoactive effects, limit drug-drug interaction, and avoid digestion of the drug by the liver.And for investors, now’s the time to start taking a closer look at Zynerba’s investing potential. That’s because this cannabis biotech is gearing up for a transformational 2019 according to five-star HC Wainwright analyst Oren Livnat. Today, Livnat reiterated his buy rating on ZYNE with a $23 price target, which indicates jaw-dropping upside of over 350%. (To watch Livnat's track record, click here)The key data to look out for comes from Zynerba’s lead Fragile X (FXS) program. ZYNE continues to enroll patients for the pivotal Phase 3 study (CONNECT-FX), and the all-important data is expected in 2H19. Livnat is optimistic for positive data, although he admits that this is a risky call given other companies’ failure in this indication.Livnat noted, "We reiterate our Buy, rating and see the current $105M market cap ($27M EV) leaving remarkable upside potential on positive data; as our $23 price target still reflects only a 35% probability of success in FXS.”Overall, this cannabis-related player stands as a 'Strong Buy' name among Wall Street analysts. In the last 12 months, ZYNE stock has won four 'buy' ratings vs. only one 'hold' rating. With a return potential of over 300%, the stock's consensus price target lands at $20. (See ZYNE's price targets and analyst ratings on TipRanks)Arena Stock Falls Under the RadarHere we have a promising biotech that is currently under-the-radar for most investors. Unlike Zynerba, Arena (ARNA) devotes some of its pipeline to CBD therapeutics, while also devoting some of its pipeline to non-cannabinoid medicine.This means that even though its most advanced drug currently in trial is Etrasimod (for colitis, Crohn’s and atopic dermatitis), for cannabis investors Olorinab is the key focus. Also known as APD371, Olorinab is an oral agonist of cannabinoid receptor 2 (CB2), which is part of the natural cannabinoid receptor system found in our bodies. The drug is designed to treat pain associated with gastrointestinal diseases like IBS and Crohn’s- a large and growing market.And the best part is that these drugs could ultimately reduce the need for highly addictive opioid medications. As Bruce Yacyshyn, medical director at UC Health University Hospital, says: “There is a strong clinical need for non-opiate treatments for the management of chronic abdominal pain in patients with gastrointestinal disorders, including Crohn’s disease, ulcerative colitis and irritable bowel syndrome.”As for the timeline, Olorinab Phase 2 trial in IBS pain is expected to begin in 2H19. Cantor Fitzgerald’s Alethia Young is keeping a close eye on these developments, writing “Over the next 12-18 months, we see opportunities like olorinab and etrasimod expansion as underappreciated at current levels. With many Ph2 and 3 trials reading out in 2020, we expect investors to take note, and we see little downside risk in the interim.”She reiterates her buy rating on Arena with a $62 price target- indicating 33% upside potential from current levels. Alongside Young, Needham’s Alan Carr is the only other top analyst who has published a recent rating on Arena. He also rates the stock a Buy, writing “we think olorinab remains an unappreciated potential opportunity with commercial synergies with etrasimod.”To read more on the nitty gritty of what’s going on in the rising cannabis industry, click here. More recent articles from Smarter Analyst: * Is Tesla (TSLA) Stock on Brink After Poor Deliveries Report? * Can iPhone Trade-Ins Help Boost Apple (AAPL) Stock? * Why Tesla (TSLA) Stock Is Headed in the Wrong Direction * This Cannabis Stock Is a Compelling Investment Story
